Semanteon Capital Management LP Invests $1.14 Million in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Semanteon Capital Management LP purchased a new stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 149,576 shares of the biotechnology company's stock, valued at approximately $1,137,000. Semanteon Capital Management LP owned approximately 0.07% of BioCryst Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. CWM LLC grew its holdings in shares of BioCryst Pharmaceuticals by 200.0% during the second quarter. CWM LLC now owns 5,658 shares of the biotechnology company's stock valued at $35,000 after buying an additional 3,772 shares in the last quarter. Signaturefd LLC boosted its position in BioCryst Pharmaceuticals by 560.5% during the 2nd quarter. Signaturefd LLC now owns 6,598 shares of the biotechnology company's stock worth $41,000 after acquiring an additional 5,599 shares during the period. Seven Eight Capital LP purchased a new position in BioCryst Pharmaceuticals during the 1st quarter valued at about $57,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of BioCryst Pharmaceuticals by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company's stock valued at $57,000 after purchasing an additional 1,322 shares during the period. Finally, Natixis lifted its position in shares of BioCryst Pharmaceuticals by 400.6% in the first quarter. Natixis now owns 11,684 shares of the biotechnology company's stock worth $59,000 after purchasing an additional 9,350 shares in the last quarter. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Stock Up 2.5 %

Shares of BCRX stock traded up $0.20 during mid-day trading on Monday, reaching $8.15. The stock had a trading volume of 1,475,915 shares, compared to its average volume of 2,955,986. BioCryst Pharmaceuticals, Inc. has a one year low of $4.03 and a one year high of $8.88. The firm has a market cap of $1.68 billion, a PE ratio of -7.62 and a beta of 1.88. The firm's 50 day simple moving average is $7.84 and its 200 day simple moving average is $6.83.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last posted its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($0.06) earnings per share for the quarter, topping analysts' consensus estimates of ($0.17) by $0.11. The business had revenue of $109.30 million for the quarter, compared to analyst estimates of $98.30 million. During the same quarter in the prior year, the firm earned ($0.24) EPS. The firm's quarterly revenue was up 34.9% on a year-over-year basis. Sell-side analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.38 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently commented on BCRX shares. HC Wainwright reaffirmed a "buy" rating and set a $30.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, August 6th. JMP Securities lifted their price objective on BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the company a "market outperform" rating in a research report on Tuesday, August 6th. Royal Bank of Canada restated an "outperform" rating and issued a $10.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, August 6th. Barclays raised their price target on BioCryst Pharmaceuticals from $6.00 to $7.00 and gave the stock an "equal weight" rating in a research note on Tuesday, August 6th. Finally, StockNews.com upgraded shares of BioCryst Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Tuesday, August 6th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $14.17.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.